Referenser

Abbasakoor, F., & Boulos, P. B. (2005). Anal intraepithelial neoplasia. Br J Surg, 92(3), 277-290. doi:10.1002/bjs.4967

Adams, E., Boulton, M. G., Horne, A., Rose, P. W., Durrant, L., Collingwood, M., . . . Watson, E. K. (2014). The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol), 26(1), 10-17. doi:10.1016/j.clon.2013.08.003

Agarwal, A., Marcus, C., Xiao, J., Nene, P., Kachnic, L. A., & Subramaniam, R. M. (2014). FDG PET/CT in the management of colorectal and anal cancers. AJR Am J Roentgenol, 203(5), 1109-1119. doi:10.2214/ajr.13.12256

Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., . . . Willett, C. (2008). Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. Jama, 299(16), 1914-1921. doi:10.1001/jama.299.16.1914

Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., . . . Willett, C. G. (2009). US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol, 27(7), 1116-1121. doi:10.1200/jco.2008.19.6857

Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., . . . Willett, C. G. (2010). Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer, 116(17), 4007-4013. doi:10.1002/cncr.25188

Anderson, C., Koshy, M., Staley, C., Esiashvili, N., Ghavidel, S., Fowler, Z., . . . Godette, K. (2007). PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys, 69(1), 155-162. doi:10.1016/j.ijrobp.2007.02.055

Andreyev, H. J., Muls, A. C., Norton, C., Ralph, C., Watson, L., Shaw, C., & Lindsay, J. O. (2015). Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease. Frontline Gastroenterol, 6(1), 53-72. doi:10.1136/flgastro-2014-100468

Andreyev, J. (2007). Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol, 8(11), 1007-1017. doi:10.1016/s1470-2045(07)70341-8

Avallone, A., Aloj, L., Caraco, C., Delrio, P., Pecori, B., Tatangelo, F., . . . Lastoria, S. (2012). Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging, 39(12), 1848-1857. doi:10.1007/s00259-012-2229-2

Balleyguier, C., Sala, E., Da Cunha, T., Bergman, A., Brkljacic, B., Danza, F., . . . Kinkel, K. (2011). Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol, 21(5), 1102-1110. doi:10.1007/s00330-010-1998-x

Bartelink, H., Roelofsen, F., Eschwege, F., Rougier, P., Bosset, J. F., Gonzalez, D. G., . . . Pierart, M. (1997). Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol, 15(5), 2040-2049. 

Bentzen, A. G., Balteskard, L., Wanderas, E. H., Frykholm, G., Wilsgaard, T., Dahl, O., & Guren, M. G. (2013). Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol, 52(4), 736-744. doi:10.3109/0284186x.2013.770599

Bentzen, A. G., Guren, M. G., Wanderas, E. H., Frykholm, G., Tveit, K. M., Wilsgaard, T., . . . Balteskard, L. (2012). Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys, 83(2), e173-180. doi:10.1016/j.ijrobp.2011.12.062

Bentzen, A. G., Guren, M. G., Vonen, B., Wanderas, E. H., Frykholm, G., Wilsgaard, T., . . . Balteskard, L. (2013). Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiother Oncol, 108(1), 55-60. doi:10.1016/j.radonc.2013.05.037

Bentzen, S. M., Constine, L. S., Deasy, J. O., Eisbruch, A., Jackson, A., Marks, L. B., . . . Yorke, E. D. (2010). Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys, 76(3 Suppl), S3-9. doi:10.1016/j.ijrobp.2009.09.040

Bhuva, N. J., Glynne-Jones, R., Sonoda, L., Wong, W. L., & Harrison, M. K. (2012). To PET or not to PET? That is the question. Staging in anal cancer. Ann Oncol, 23(8), 2078-2082. doi:10.1093/annonc/mdr599

Bosman, F. T., Carneiro, F., Hruban, R.H., Theise, N.D. (2010). WHO Classification of Tumours of the Digestive System, Fourth Edition 

Braendengen, M., Hansson, K., Radu, C., Siegbahn, A., Jacobsson, H., & Glimelius, B. (2011). Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study. Int J Radiat Oncol Biol Phys, 81(4), e439-445. doi:10.1016/j.ijrobp.2011.03.031

Branagan, G. (2011). Staging and management of inguinal nodes. Colorectal Dis, 13 Suppl 1, 29-32. doi:10.1111/j.1463-1318.2010.02496.x

Brierley, J. D., Gospodarowicz, M.K., Wittekind, C. (2009). TNM Classification of Malignant Tumours, 7th Edition: November 2009, Wiley-Blackwell.

Bruna, A., Gastelblum, P., Thomas, L., Chapet, O., Bollet, M. A., Ardiet, J. M., . . . Peiffert, D. (2006). Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. Radiother Oncol, 79(1), 75-79. doi:10.1016/j.radonc.2006.03.013

Caldarella, C., Annunziata, S., Treglia, G., Sadeghi, R., Ayati, N., & Giovanella, L. (2014). Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. ScientificWorldJournal, 2014, 196068. doi:10.1155/2014/196068

Cascini, G. L., Avallone, A., Delrio, P., Guida, C., Tatangelo, F., Marone, P., . . . Lastoria, S. (2006). 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med, 47(8), 1241-1248. 

Chan, R. J., Larsen, E., & Chan, P. (2012). Re-examining the evidence in radiation dermatitis management literature: an overview and a critical appraisal of systematic reviews. Int J Radiat Oncol Biol Phys, 84(3), e357-362. doi:10.1016/j.ijrobp.2012.05.009

Charnley, N., Choudhury, A., Chesser, P., Cooper, R. A., & Sebag-Montefiore, D. (2005). Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. Br J Cancer, 92(7), 1221-1225. doi:10.1038/sj.bjc.6602486

Choi, H. J., Ju, W., Myung, S. K., & Kim, Y. (2010). Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci, 101(6), 1471-1479. doi:10.1111/j.1349-7006.2010.01532.x

Clark, M. A., Hartley, A., & Geh, J. I. (2004). Cancer of the anal canal. Lancet Oncol, 5(3), 149-157. doi:10.1016/s1470-2045(04)01410-x

Cox, J. D., Stetz, J., & Pajak, T. F. (1995). Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31(5), 1341-1346. doi:10.1016/0360-3016(95)00060-c

Dapper, H., Oechsner, M., Hirche, C., Munch, S., Sauter, C., Borm, K., . . . Habermehl, D. (2018). Dosimetric comparison of different radiation techniques (IMRT vs. 3-dimensional) of the "true" (deep) ano-inguinal lymphatic drainage of anal cancer patients. Radiat Oncol, 13(1), 227. doi:10.1186/s13014-018-1174-z

Das, P., Bhatia, S., Eng, C., Ajani, J. A., Skibber, J. M., Rodriguez-Bigas, M. A., . . . Crane, C. H. (2007). Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys, 68(3), 794-800. doi:10.1016/j.ijrobp.2006.12.052

Dewdney, A., & Rao, S. (2012). Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? ISRN Oncol, 2012, 756591. doi:10.5402/2012/756591

Dujovny, N., Quiros, R. M., & Saclarides, T. J. (2004). Anorectal anatomy and embryology. Surg Oncol Clin N Am, 13(2), 277-293. doi:10.1016/j.soc.2004.01.002

Dunberger, G., & Bergmark, K. (2012). Nurse-led care for the management of side effects of pelvic radiotherapy: what does it achieve? Curr Opin Support Palliat Care, 6(1), 60-68. doi:10.1097/SPC.0b013e32834f6a95

Durot, C., Dohan, A., Boudiaf, M., Servois, V., Soyer, P., & Hoeffel, C. (2017). Cancer of the Anal Canal: Diagnosis, Staging and Follow-Up with MRI. Korean J Radiol, 18(6), 946-956. doi:10.3348/kjr.2017.18.6.946

Ehrenpreis, E. D., Marsh, R de W, Small Jr., W. . (2015). Radiation Therapy for Pelvic Malignancy and its Consequences. New York: Springer.

Eng, C., Chang, G. J., You, Y. N., Das, P., Rodriguez-Bigas, M., Xing, Y., . . . Wolff, R. A. (2014). The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget, 5(22), 11133-11142. doi:10.18632/oncotarget.2563

Engstrom, P. F., Arnoletti, J. P., Benson, A. B., 3rd, Berlin, J. D., Berry, J. M., Chen, Y. J., . . . Willett, C. (2010). NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw, 8(1), 106-120. 

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. (1996). Lancet, 348(9034), 1049-1054. 

Feight, D., Baney, T., Bruce, S., & McQuestion, M. (2011). Putting evidence into practice. Clin J Oncol Nurs, 15(5), 481-492. doi:10.1188/11.cjon.481-492

Fenger, C. (1987). The anal transitional zone. Acta Pathol Microbiol Immunol Scand Suppl, 289, 1-42. 

Flam, M., John, M., Pajak, T. F., Petrelli, N., Myerson, R., Doggett, S., . . . Murray, K. (1996). Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol, 14(9), 2527-2539. 

Fowler, C., Kirschner, M., Van Kuiken, D., & Baas, L. (2007). Promoting self-care through symptom management: a theory-based approach for nurse practitioners. J Am Acad Nurse Pract, 19(5), 221-227. doi:10.1111/j.1745-7599.2007.00218.x

Franceschi, S., & De Vuyst, H. (2009). Human papillomavirus vaccines and anal carcinoma. Curr Opin HIV AIDS, 4(1), 57-63. doi:10.1097/COH.0b013e32831b9c81

Gilbert, D. C., Williams, A., Allan, K., Stokoe, J., Jackson, T., Linsdall, S., . . . Summers, J. (2013). p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiother Oncol, 109(1), 146-151. doi:10.1016/j.radonc.2013.08.002

Glynne-Jones, R., Meadows, H., Wan, S., Gollins, S., Leslie, M., Levine, E., . . . Sebag-Montefiore, D. (2008). EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys, 72(1), 119-126. doi:10.1016/j.ijrobp.2007.12.012

Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol, 40(10), 1165-1176. doi:10.1016/j.ejso.2014.07.030

Glynne-Jones, R., Northover, J. M., & Cervantes, A. (2010). Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v87-92. doi:10.1093/annonc/mdq171

Goh, V., Gollub, F. K., Liaw, J., Wellsted, D., Przybytniak, I., Padhani, A. R., & Glynne-Jones, R. (2010). Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys, 78(3), 715-721. doi:10.1016/j.ijrobp.2009.08.055

Golub, D. V., Civelek, A. C., & Sharma, V. R. (2011). A regimen of taxol, Ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract, 2011, 163736. doi:10.1155/2011/163736

Goodman, K. A., Julie, D., Cercek, A., Cambridge, L., Woo, K. M., Zhang, Z., . . . Saltz, L. B. (2017). Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. Int J Radiat Oncol Biol Phys, 98(5), 1087-1095. doi:10.1016/j.ijrobp.2017.03.022

Hallemeier, C. L., You, Y. N., Larson, D. W., Dozois, E. J., Nelson, H., Klein, K. A., . . . Haddock, M. G. (2014). Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Dis Colon Rectum, 57(4), 442-448. doi:10.1097/dcr.0000000000000071

Hannoun-Levi, J. M., Ortholan, C., Resbeut, M., Teissier, E., Ronchin, P., Cowen, D., . . . Gerard, J. P. (2011). High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). Int J Radiat Oncol Biol Phys, 80(3), 712-720. doi:10.1016/j.ijrobp.2010.02.055

Hatfield, P., Cooper, R., & Sebag-Montefiore, D. (2008). Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys, 70(2), 419-424. doi:10.1016/j.ijrobp.2007.06.072

Henkenberens, C., Meinecke, D., Michael, S., Bremer, M., & Christiansen, H. (2015). Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots? Strahlenther Onkol, 191(11), 845-854. doi:10.1007/s00066-015-0885-4

Hequet, D., Marchand, E., Place, V., Fourchotte, V., De La Rochefordiere, A., Dridi, S., . . . Barranger, E. (2013). Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study. Eur J Surg Oncol, 39(12), 1428-1434. doi:10.1016/j.ejso.2013.10.006

Holliday, E. B., Lester, S. C., Harmsen, W. S., Eng, C., Haddock, M. G., Krishnan, S., . . . Hallemeier, C. L. (2018). Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. Int J Radiat Oncol Biol Phys, 102(1), 102-108. doi:10.1016/j.ijrobp.2018.04.076

Hollinworth, H., & Mann, L. (2010). Managing acute skin reactions to radiotherapy treatment. Nurs Stand, 24(24), 53-54, 56, 58 passim. doi:10.7748/ns2010.02.24.24.53.c7558

James, R. D., Glynne-Jones, R., Meadows, H. M., Cunningham, D., Myint, A. S., Saunders, M. P., . . . Sebag-Montefiore, D. (2013). Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol, 14(6), 516-524. doi:10.1016/s1470-2045(13)70086-x

Jones, C. M., Adams, R., Downing, A., Glynne-Jones, R., Harrison, M., Hawkins, M., . . . Muirhead, R. (2018). Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. Int J Radiat Oncol Biol Phys, 101(5), 1202-1211. doi:10.1016/j.ijrobp.2018.04.033

Jones, M., Hruby, G., Solomon, M., Rutherford, N., & Martin, J. (2015). The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. Ann Surg Oncol, 22(11), 3574-3581. doi:10.1245/s10434-015-4391-9

Kim, S., Francois, E., Andre, T., Samalin, E., Jary, M., El Hajbi, F., . . . Borg, C. (2018). Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol, 19(8), 1094-1106. doi:10.1016/s1470-2045(18)30321-8

Kochhar, R., Renehan, A. G., Mullan, D., Chakrabarty, B., Saunders, M. P., & Carrington, B. M. (2017). The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer. Eur Radiol, 27(2), 607-617. doi:10.1007/s00330-016-4337-z

Kreftsykepleie/under redaktion av Anne Marie Reitan och Tore Kr. Schölberg. (2010). Oslo: Akribe.

Kriterier som ska utmärka ett regionalt cancercentrum (RCC). (2011).  Retrieved from https://www.cancercentrum.se/globalassets/vara-uppdrag/rcckriterier_31jan11.pdf

Kumar, S., Juresic, E., Barton, M., & Shafiq, J. (2010). Management of skin toxicity during radiation therapy: a review of the evidence. J Med Imaging Radiat Oncol, 54(3), 264-279. doi:10.1111/j.1754-9485.2010.02170.x

Lefevre, J. H., Parc, Y., Kerneis, S., Shields, C., Touboul, E., Chaouat, M., & Tiret, E. (2009). Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg, 250(5), 707-711. doi:10.1097/SLA.0b013e3181bce334

Leon, O., Guren, M., Hagberg, O., Glimelius, B., Dahl, O., Havsteen, H., . . . Johnsson, A. (2014). Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiother Oncol, 113(3), 352-358. doi:10.1016/j.radonc.2014.10.002

Leon, O., Hagberg, O., & Johnsson, A. (2018). Primary surgery with or without postoperative radiotherapy in early stage squamous cell carcinoma in the anal canal and anal margin. Acta Oncol, 57(9), 1209-1215. doi:10.1080/0284186x.2018.1442931

Lepinoy, A., Lescut, N., Puyraveau, M., Caubet, M., Boustani, J., Lakkis, Z., . . . Bosset, J. F. (2015). Evaluation of a 36 Gy elective node irradiation dose in anal cancer. Radiother Oncol, 116(2), 197-201. doi:10.1016/j.radonc.2015.07.050

Loren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Magdalinski, A. J., Partridge, A. H., . . . Oktay, K. (2013). Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 31(19), 2500-2510. doi:10.1200/jco.2013.49.2678

Lukan, N., Strobel, P., Willer, A., Kripp, M., Dinter, D., Mai, S., . . . Hofheinz, R. D. (2009). Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology, 77(5), 293-299. doi:10.1159/000259615

Lund, J. A., Wibe, A., Sundstrom, S. H., Haaverstad, R., Kaasa, S., & Myrvold, H. E. (2007). Anal carcinoma in mid-Norway 1970-2000. Acta Oncol, 46(7), 1019-1026. doi:10.1080/02841860601166933

MacBride, S. K., Wells, M. E., Hornsby, C., Sharp, L., Finnila, K., & Downie, L. (2008). A case study to evaluate a new soft silicone dressing, Mepilex Lite, for patients with radiation skin reactions. Cancer Nurs, 31(1), E8-14. doi:10.1097/01.ncc.0000305680.06143.39

Mahmud, A., Poon, R., & Jonker, D. (2017). PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol, 90(1080), 20170370. doi:10.1259/bjr.20170370

Mai, S., Welzel, G., Ottstadt, M., Lohr, F., Severa, S., Prigge, E. S., . . . Reuschenbach, M. (2015). Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. Int J Radiat Oncol Biol Phys, 93(4), 819-827. doi:10.1016/j.ijrobp.2015.08.004

Matzinger, O., Roelofsen, F., Mineur, L., Koswig, S., Van Der Steen-Banasik, E. M., Van Houtte, P., . . . Bosset, J. F. (2009). Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer, 45(16), 2782-2791. doi:10.1016/j.ejca.2009.06.020

Meulendijks, D., Dewit, L., Tomasoa, N. B., van Tinteren, H., Beijnen, J. H., Schellens, J. H., & Cats, A. (2014). Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer, 111(9), 1726-1733. doi:10.1038/bjc.2014.467

Miles, T., & Johnson, N. (2014). Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev(9), Cd007291. doi:10.1002/14651858.CD007291.pub3

Mistrangelo, M., Pelosi, E., Bello, M., Ricardi, U., Milanesi, E., Cassoni, P., . . . Morino, M. (2012). Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys, 84(1), 66-72. doi:10.1016/j.ijrobp.2011.10.048

Muirhead, R. (2016, 18/04/2016). National guidance for IMRT in Anal Cancer. 3rd edition. . Retrieved from http://analimrtguidance.co.uk/national-anal-imrt-guidance-v3.pdf

Murthy, V., & Gopinath, K. S. (2012). Reconstruction of groin defects following radical inguinal lymphadenectomy: an evidence based review. Indian J Surg Oncol, 3(2), 130-138. doi:10.1007/s13193-012-0145-3

Myerson, R. J., Garofalo, M. C., El Naqa, I., Abrams, R. A., Apte, A., Bosch, W. R., . . . Kachnic, L. A. (2009). Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys, 74(3), 824-830. doi:10.1016/j.ijrobp.2008.08.070

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Anal Carcinoma. Version 2. 2017 - April 20, 2017. (2017). Retrieved from https://www.nccn.org/professionals/physician_gls/default.aspx

Ng, M., Leong, T., Chander, S., Chu, J., Kneebone, A., Carroll, S., . . . Kachnic, L. (2012). Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys, 83(5), 1455-1462. doi:10.1016/j.ijrobp.2011.12.058

Niehoff, P., & Kovacs, G. (2014). HDR brachytherapy for anal cancer. J Gastrointest Oncol, 5(3), 218-222. doi:10.3978/j.issn.2078-6891.2014.027

Nigro, N. D., Seydel, H. G., Considine, B., Vaitkevicius, V. K., Leichman, L., & Kinzie, J. J. (1983). Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer, 51(10), 1826-1829. 

Nigro, N. D., Vaitkevicius, V. K., & Considine, B., Jr. (1974). Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum, 17(3), 354-356. 

Oh, C. C., Ko, H. C., Lee, H. Y., Safdar, N., Maki, D. G., & Chlebicki, M. P. (2014). Antibiotic prophylaxis for preventing recurrent cellulitis: a systematic review and meta-analysis. J Infect, 69(1), 26-34. doi:10.1016/j.jinf.2014.02.011

Oliveira, S. C., Moniz, C. M., Riechelmann, R., Alex, A. K., Braghirolli, M. I., Bariani, G., . . . Hoff, P. M. (2016). Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. J Gastrointest Cancer, 47(1), 75-81. doi:10.1007/s12029-015-9790-4

Pape, H., Orth, K., Heese, A., Heyll, A., Kobbe, G., Schmitt, G., . . . Boelke, E. (2006). G-CSF during large field radiotherapy reduces bone marrow recovery capacity. Eur J Med Res, 11(8), 322-328. 

Pawlik, T. M., Gleisner, A. L., Bauer, T. W., Adams, R. B., Reddy, S. K., Clary, B. M., . . . Elias, D. (2007). Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol, 14(10), 2807-2816. doi:10.1245/s10434-007-9467-8

Peiffert, D., Tournier-Rangeard, L., Gerard, J. P., Lemanski, C., Francois, E., Giovannini, M., . . . Ducreux, M. (2012). Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol, 30(16), 1941-1948. doi:10.1200/jco.2011.35.4837

Peixoto, R. D., Wan, D. D., Schellenberg, D., & Lim, H. J. (2016). A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer. J Gastrointest Oncol, 7(4), 665-672. doi:10.21037/jgo.2016.06.04

Rao, S., Sclafani, F., Eng, C., Grönlie Guren, M., Adams, R. A., Benson, A. B., . . . Arnold, D. (2018). InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. . Paper presented at the European Society of Medical Oncology annual meeting. . 

Renehan, A. G., & O'Dwyer, S. T. (2011). Management of local disease relapse. Colorectal Dis, 13 Suppl 1, 44-52. doi:10.1111/j.1463-1318.2010.02500.x

Roed, H., Engelholm, S. A., Svendsen, L. B., Rosendal, F., & Olsen, K. J. (1996). Pulsed dose rate (PDR) brachytherapy of anal carcinoma. Radiother Oncol, 41(2), 131-134. 

Rogers, J. E., Silva, N. N., & Eng, C. (2015). Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. J Gastrointest Oncol, 6(5), E82-85. doi:10.3978/j.issn.2078-6891.2015.035

Saboo, S. S., Zukotynski, K., Shinagare, A. B., Krajewski, K. M., & Ramaiya, N. (2013). Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up. Abdom Imaging, 38(4), 728-735. doi:10.1007/s00261-012-9958-3

Saint, A., Evesque, L., Falk, A. T., Cavaglione, G., Montagne, L., Benezery, K., & Francois, E. (2019). Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. Cancer Med, 8(16), 6853-6859. doi:10.1002/cam4.2558

Salit, I. E., Lytwyn, A., Raboud, J., Sano, M., Chong, S., Diong, C., . . . Tinmouth, J. (2010). The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. Aids, 24(9), 1307-1313. doi:10.1097/QAD.0b013e328339e592

Sekhar, H., Zwahlen, M., Trelle, S., Malcomson, L., Kochhar, R., Saunders, M. P., . . . Renehan, A. G. (2017). Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. Lancet Oncol, 18(10), 1348-1359. doi:10.1016/s1470-2045(17)30456-4

Serup-Hansen, E., Linnemann, D., Skovrider-Ruminski, W., Hogdall, E., Geertsen, P. F., & Havsteen, H. (2014). Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol, 32(17), 1812-1817. doi:10.1200/jco.2013.52.3464

Sheikh, H., Colaco, R., Lorigan, P., Blackhall, F., Califano, R., Ashcroft, L., . . . Faivre-Finn, C. (2011). Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer, 74(1), 75-79. doi:10.1016/j.lungcan.2011.01.020

Simpson, J. A., & Scholefield, J. H. (2011). Diagnosis and management of anal intraepithelial neoplasia and anal cancer. Bmj, 343, d6818. doi:10.1136/bmj.d6818

Socialdepartementet. (2009). SOU 2009:11, En nationell cancerstrategi för framtiden.  Retrieved from http://www.regeringen.se/rattsdokument/statens-offentliga-utredningar/2009/02/sou-200911/

Somoye, G., Harry, V., Semple, S., Plataniotis, G., Scott, N., Gilbert, F. J., & Parkin, D. (2012). Early diffusion weighted magnetic resonance imaging can predict survival in women with locally advanced cancer of the cervix treated with combined chemo-radiation. Eur Radiol, 22(11), 2319-2327. doi:10.1007/s00330-012-2496-0

Staar, S., Rudat, V., Stuetzer, H., Dietz, A., Volling, P., Schroeder, M., . . . Mueller, R. P. (2001). Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys, 50(5), 1161-1171. 

Sunesen, K. G., Buntzen, S., Tei, T., Lindegaard, J. C., Norgaard, M., & Laurberg, S. (2009). Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol, 16(1), 68-77. doi:10.1245/s10434-008-0208-4

Swan, M. C., Furniss, D., & Cassell, O. C. (2004). Surgical management of metastatic inguinal lymphadenopathy. Bmj, 329(7477), 1272-1276. doi:10.1136/bmj.329.7477.1272

Thind, G., Johal, B., Follwell, M., & Kennecke, H. F. (2014). Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. Radiat Oncol, 9, 124. doi:10.1186/1748-717x-9-124

Thomé B., H. M. (2011). Perspektiv på onkologisk vård: Studentlitteratur.

Walts, A. E., Lechago, J., & Bose, S. (2006). P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia. Am J Surg Pathol, 30(7), 795-801. doi:10.1097/01.pas.0000208283.14044.a9

Wedlake, L., Shaw, C., McNair, H., Lalji, A., Mohammed, K., Klopper, T., . . . Andreyev, H. J. N. (2017). Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. Am J Clin Nutr, 106(3), 849-857. doi:10.3945/ajcn.116.150565

Wendell-Smith, C. P. (2000). Anorectal nomenclature: fundamental terminology. Dis Colon Rectum, 43(10), 1349-1358. 

Vercellino, L., Montravers, F., de Parades, V., Huchet, V., Kerrou, K., Bauer, P., . . . Talbot, J. N. (2011). Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. Int J Colorectal Dis, 26(2), 201-210. doi:10.1007/s00384-010-1080-9

Wright, J. L., Patil, S. M., Temple, L. K., Minsky, B. D., Saltz, L. B., & Goodman, K. A. (2010). Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys, 78(4), 1064-1072. doi:10.1016/j.ijrobp.2009.09.029

Young, P., Daniel, B., Sommer, G., Kim, B., & Herfkens, R. (2012). Intravaginal gel for staging of female pelvic cancers--preliminary report of safety, distention, and gel-mucosal contrast during magnetic resonance examination. J Comput Assist Tomogr, 36(2), 253-256. doi:10.1097/RCT.0b013e3182483c05